Stock Scorer

Bio Essence Corp (BIOE)

Bio Essence Corp reported revenue of 794.7K USD for the quarter ending 30 June 2026, up 206.7% from 259.1K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 794.7K +206.7%
Gross Profit Q2 '26 · ending 30 June 2026 470.3K +178.8%
Operating Income Q2 '26 · ending 30 June 2026 279.3K +356.2%
Net Income Q2 '26 · ending 30 June 2026 270.1K +351.2%
Cost of Revenue Q2 '26 · ending 30 June 2026 324.4K +258.6%
Operating Cash Flow Q2 '26 · ending 30 June 2026 59.6K -64.5%
Free Cash Flow Q4 '23 · ending 31 December 2023 -204.1K —
Shares Outstanding Q2 '26 · ending 30 June 2026 50.9M +33.9%
EPS Q2 '25 · ending 30 June 2025 -0.04 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 1.9M900K896.2K—
20242024-12-31 323.9K-459.4K-1.3M—
20232023-12-31 551.5K-345.6K-971.9K-1M
20222022-12-31 621.6K-511.1K-809.7K-707K
20212021-12-31 888K-857.5K-647.6K-1.4M
20202020-12-31 958.7K-832.6K-595.8K-740.1K

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-30794.7K
Q1 '262026-03-31500.5K
Q4 '252025-12-311.5M
Q3 '252025-09-30136.8K
Q2 '252025-06-30259.1K
Q1 '252025-03-3122.2K
Q4 '242024-12-31147.6K
Q3 '242024-09-30134.7K
Q2 '242024-06-3041.7K
Q3 '232023-09-30155.7K
Q2 '232023-06-30259.6K
Q1 '232023-03-31341.3K
Q3 '222022-09-30192.1K
Q2 '222022-06-30288.1K
Q1 '222022-03-31306.4K
Q4 '212021-12-31213K
Q3 '212021-09-30227K
Q2 '212021-06-30235.9K
Q1 '212021-03-31212K
Q4 '202020-12-31218.9K

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '262026-06-30470.3K
Q1 '262026-03-31319.4K
Q4 '252025-12-311.1M
Q3 '252025-09-3095.8K
Q2 '252025-06-30168.6K
Q1 '252025-03-3120.6K
Q4 '242024-12-31106.9K
Q3 '242024-09-3081K
Q2 '242024-06-3029.2K
Q3 '232023-09-3020.2K
Q2 '232023-06-30109.7K
Q1 '232023-03-31166.5K
Q4 '222022-12-3114K
Q3 '222022-09-3086.5K
Q2 '222022-06-30157.3K
Q1 '222022-03-3170.5K
Q4 '212021-12-3161.7K
Q3 '212021-09-3095.4K
Q2 '212021-06-3064.5K
Q1 '212021-03-3176.7K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30279.3K
Q1 '262026-03-31215.8K
Q4 '252025-12-311M
Q3 '252025-09-3014.3K
Q2 '252025-06-3061.2K
Q1 '252025-03-31-205.1K
Q4 '242024-12-313.9K
Q3 '242024-09-30-146.4K
Q2 '242024-06-30-165K
Q1 '242024-03-31-151.8K
Q4 '232023-12-31-195.5K
Q3 '232023-09-30-82.6K
Q2 '232023-06-30-43.2K
Q1 '232023-03-31-24.3K
Q4 '222022-12-3163.8K
Q3 '222022-09-30-192.6K
Q2 '222022-06-30-155.9K
Q1 '222022-03-31-226.4K
Q4 '212021-12-31-198.8K
Q3 '212021-09-30-192.9K

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30270.1K
Q1 '262026-03-31205.4K
Q4 '252025-12-311M
Q3 '252025-09-3013K
Q2 '252025-06-3059.9K
Q1 '252025-03-31-205.8K
Q4 '242024-12-31-27.6K
Q3 '242024-09-30-1.2M
Q2 '242024-06-30-215.7K
Q1 '242024-03-31133.9K
Q4 '232023-12-31-193.7K
Q3 '232023-09-30-314.8K
Q2 '232023-06-30-284.5K
Q1 '232023-03-31-178.8K
Q4 '222022-12-31-213.1K
Q3 '222022-09-30-199.2K
Q2 '222022-06-30-164.2K
Q1 '222022-03-31-233.1K
Q4 '212021-12-31-90.6K
Q3 '212021-09-30-183K

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-30324.4K
Q1 '262026-03-31181.2K
Q4 '252025-12-31336K
Q3 '252025-09-3041K
Q2 '252025-06-3090.5K
Q1 '252025-03-311.6K
Q4 '242024-12-3140.7K
Q3 '242024-09-3053.7K
Q2 '242024-06-3012.5K
Q3 '232023-09-30135.4K
Q2 '232023-06-30149.9K
Q1 '232023-03-31174.8K
Q3 '222022-09-30105.5K
Q2 '222022-06-30130.8K
Q1 '222022-03-31236K
Q4 '212021-12-31151.3K
Q3 '212021-09-30131.6K
Q2 '212021-06-30171.4K
Q1 '212021-03-31135.3K
Q4 '202020-12-31281K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-3059.6K
Q1 '262026-03-31-412K
Q4 '252025-12-311.2M
Q3 '252025-09-30187K
Q2 '252025-06-30167.8K
Q1 '252025-03-31-26.1K
Q4 '242024-12-31423.1K
Q3 '242024-09-30357.1K
Q2 '242024-06-3015.3K
Q1 '242024-03-31-171.6K
Q4 '232023-12-31-204.1K
Q3 '232023-09-30-344.8K
Q2 '232023-06-30-245K
Q1 '232023-03-31-231.7K
Q4 '222022-12-31-129.3K
Q3 '222022-09-30-130.3K
Q2 '222022-06-30-189.2K
Q1 '222022-03-31-254.5K
Q4 '212021-12-31-142.6K
Q3 '212021-09-30-173.1K

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '232023-12-31-204.1K
Q4 '222022-12-31-134.8K
Q3 '222022-09-30-182.3K
Q4 '212021-12-31-232.4K
Q3 '212021-09-30-182.1K
Q2 '212021-06-30-830.9K
Q1 '212021-03-31-168.2K
Q4 '202020-12-31-242.5K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3050.9M
Q1 '262026-03-3145M
Q3 '252025-09-3038M
Q2 '252025-06-3038M
Q1 '252025-03-3138M
Q3 '242024-09-3038M
Q2 '242024-06-3038M
Q1 '242024-03-3138M
Q3 '232023-09-3038M
Q2 '232023-06-3034.7M
Q1 '232023-03-3133M
Q3 '222022-09-3033M
Q2 '222022-06-3033M
Q1 '222022-03-3133M
Q3 '212021-09-3033M
Q2 '212021-06-3033M
Q1 '212021-03-3133M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '252025-06-30-0.04
Q1 '252025-03-31-0.05
Q4 '242024-12-31-0.04
Q3 '242024-09-30-0.05
Q2 '242024-06-30-0.03
Q1 '242024-03-31-0.03
Q4 '232023-12-31-0.04
Q3 '232023-09-30-0.03
Q2 '232023-06-30-0.03
Q1 '232023-03-31-0.02
Q4 '222022-12-31-0.02
Q3 '222022-09-30-0.02
Q2 '222022-06-30-0.02
Q1 '222022-03-31-0.02
Q4 '212021-12-31-0.02
Q3 '212021-09-30-0.02
Q2 '212021-06-30-0.02
Q1 '212021-03-31-0.03
Q4 '202020-12-31-0.02